Loading...
XJPX
4559
Market cap617mUSD
Jul 15, Last price  
2,069.00JPY
1D
0.39%
1Q
-8.61%
Jan 2017
14.69%
Name

Zeria Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
11.80
P/S
1.20
EPS
175.39
Div Yield, %
2.17%
Shrs. gr., 5y
-2.35%
Rev. gr., 5y
4.14%
Revenues
75.73b
+10.74%
55,564,507,00052,765,307,00049,756,754,00047,669,528,00050,761,809,00049,514,364,00053,194,487,00053,324,984,00061,991,881,00061,060,954,00062,479,030,00064,860,181,00064,577,699,00061,823,760,00060,435,230,00055,431,725,00059,532,829,00068,383,227,00075,725,075,000
Net income
7.73b
+24.78%
1,248,763,0002,068,188,0001,639,098,0001,203,139,0001,001,776,0001,842,695,0002,861,017,0003,982,226,0005,277,080,0002,557,646,0003,513,496,0003,544,359,0004,157,810,0003,454,098,0002,925,375,0003,143,125,0003,961,184,0006,195,865,0007,731,261,000
CFO
12.18b
-7.40%
1,265,510,0002,749,235,0003,759,286,000423,628,0005,858,132,0005,847,559,0006,028,426,0003,878,531,0006,573,328,000653,283,0005,694,606,0007,238,497,0008,821,935,0005,500,730,0007,251,345,0006,894,290,0008,950,932,00013,157,415,00012,183,609,000
Dividend
Sep 29, 20250 JPY/sh

Profile

Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents in Japan and internationally. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn's disease, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; therapeutic agents for hypophosphatemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; sclerosing agent for varicose veins; anti-inflammatory topical blood circulation enhancers; non-steroidal anti-inflammatory ophthalmic solutions; absorbable topical hemostat products; and proton pump inhibitors. In addition, it offers consumer healthcare products, such as nutritional health drugs, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, and food for specified health uses. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Tokyo, Japan.
URL
https://www.zeria.co.jp/
IPO date
Dec 22, 1998
Employees
1,729
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
75,725,075
10.74%
68,383,227
14.87%
Cost of revenue
66,008,429
54,996,627
Unusual Expense (Income)
NOPBT
9,716,646
13,386,600
NOPBT Margin
12.83%
19.58%
Operating Taxes
1,813,185
1,065,887
Tax Rate
18.66%
7.96%
NOPAT
7,903,461
12,320,713
Net income
7,731,261
24.78%
6,195,865
56.41%
Dividends
(1,935,396)
(1,589,995)
Dividend yield
2.06%
1.60%
Proceeds from repurchase of equity
(824)
5,628,902
BB yield
0.00%
-5.68%
Debt
Debt current
38,283,000
34,890,470
Long-term debt
8,953,910
15,549,218
Deferred revenue
1,187,796
Other long-term liabilities
1,795,118
1,275,489
Net debt
17,768,032
14,048,610
Cash flow
Cash from operating activities
12,183,609
13,157,415
CAPEX
(2,900,000)
(2,657,736)
Cash from investing activities
(3,952,373)
(2,574,517)
Cash from financing activities
(8,124,090)
(7,415,068)
FCF
2,476,787
10,761,155
Balance
Cash
20,323,724
16,219,078
Long term investments
9,145,154
20,172,000
Excess cash
25,682,624
32,971,917
Stockholders' equity
86,409,476
72,260,576
Invested Capital
102,168,084
83,624,127
ROIC
8.51%
14.84%
ROCE
7.24%
10.97%
EV
Common stock shares outstanding
44,080
44,173
Price
2,132.00
-5.03%
2,245.00
17.91%
Market cap
93,978,677
-5.23%
99,169,162
15.39%
EV
111,953,462
113,448,565
EBITDA
17,272,096
19,534,870
EV/EBITDA
6.48
5.81
Interest
457,801
337,281
Interest/NOPBT
4.71%
2.52%